Navigation Links
Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
Date:2/8/2012

ROCKVILLE, Md., Feb. 8, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announces that President and CEO Richard Garr will present at the 14th Annual BIO CEO & Investor Conference 2012 in New York City on Monday, February 13, at 3:00 p.m. EST. Garr will present a business overview, and an update on the company's ongoing clinical trials in both its cell therapy and pharmaceutical divisions.

(Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO)

The webcast will be available in real-time at http://www.veracast.com/webcasts/bio/ceoinvestor2012/43114242.cfm, and again beginning one hour after the conclusion of the live event, and archived for 90 days. The webcast link will also be posted on the Investor Center home page on Neuralstem's website: www.neuralstem.com.

The BIO CEO & Investor Conference 2012 will be held at the Waldorf=Astoria in New York City, February 13-14. For more information, see: http://www.bio.org/events/conferences/14th-annual-bio-ceo-investor-conference. Now in its 14th year, the BIO CEO & Investor Conference is billed as the largest independent investor conference focused on publicly traded biotechnology companies.

Neuralstem's President and CEO Richard Garr is also scheduled to present at the 6th Annual BIO-Europe Spring Conference 2012, March 19-21, in Amsterdam, Holland. Please see http://www.ebdgroup.com/bes/index.php for more information.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia, chronic stroke, and Huntington's disease. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first small molecule compound, for the treatment of major depressive disorder (MDD).  Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For more information, please visit www.neuralstem.com and connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information                                                               

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the  quarterly report on Form 10-Q for the period ended September 30, 2011.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
2. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
3. Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
4. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
5. Neuralstem Awarded Department of Defense Contract for Brain Cancer Research
6. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
7. Former Capital One Director and Business Leader Stanley I. Westreich Joins Neuralstems Board
8. Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd.
9. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
10. Neuralstem Completes $5.25 Million Financing
11. Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a ... discoveries to the medical community, has closed its Series ... Matthew Nunez . "We have received a ... the capital we need to meet our current goals," ... provide us the runway to complete validation on the ...
(Date:6/23/2016)... Windsor, Connecticut (PRWEB) , ... June 23, 2016 ... ... will introduce a new line of intelligent tools designed, tuned and optimized exclusively ... place September 12–17 in Chicago. The result of a collaboration among several companies ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):